Intratympanic Dexamethasone for Sudden Sensorineural Hearing.pdfVIP

The Laryngoscope Lippincott Williams Wilkins, Inc. © 2006 The American Laryngological, Rhinological and Otological Society, Inc. Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss After Failure of Systemic Therapy David S. Haynes, MD; Matthew O’Malley, MD; Seth Cohen, MD; Kenneth Watford, NP; Robert F. Labadie, MD, PhD Objective: Intratympanic steroids are increas- age, time to onset of therapy, status of the contralat- ingly used in the treatment of inner ear disorders, eral ear, presence of diabetes, severity of HL, and especially in patients with sudden sensorineural presence of associated symptoms (tinnitus, vertigo). A hearing loss (SNHL) who have failed systemic ther- 20-dB gain in PTA or a 20% improvement in SDS was apy. We reviewed our experience with intratympanic considered significant. Results: Forty patients fit the steroids in the treatment of patients with sudden criteria for inclusion in the study. The mean age of the SNHL to determine overall success, morbidity, and patients was 54.8 years with a range from 17 to 84 prognostic factors. Hypothesis: Intratympanic ste- years of age. Overall, 40% (n 16) showed any im- roids have minimal morbidity and the potential to provement in PTA or SDS. Fourteen (35%) men and 26 have a positive effect on hearing recovery in patients (65%) women were included. Using the criteria of with sudden SNHL who have failed systemic therapy. 20-dB improvement in PTA or 20% improvement in Study Design: The authors conducted a retrospective SDS for success, 27.5% (n 11) showed improvement. review. Methods: Patients presenting with sudden The mean number of days from onset of symptoms to SNH